Henipaviruses like Nipah (NiV) and Hendra (HeV) are highly lethal, bat-borne zoonotic viruses from the Paramyxoviridae family that cause severe encephalitis and respiratory illness in humans and animals. These viruses are highly transmissible and have notable pandemic potential. Researchers are actively screening and testing numerous small-molecule compounds as potential treatments for henipavirus infections. A team at the University of Illinois Chicago and collaborators used a high-throughput screening approach to identify a focused library of analogues.

China Pharmaceutical University and Chongqing Innovation Institute China Pharmaceutical University have reported tetrahydronaphthyridine compounds acting as stimulator of interferon genes protein (STING; TMEM173) antagonists.

Fatty acid lipoxygenase ALOX15 inhibitors have been disclosed in a joint Teijin Pharma Ltd. and Transthera Biosciences Co. Ltd. patent. They are reported to be useful for the treatment of amyotrophic lateral sclerosis, asthma, autoimmune disease, cancer, cardiovascular disorders, epilepsy, Parkinson’s disease and allergic rhinitis, among others.

Zhuhai United Laboratories Co. Ltd. has patented boronic acid β-lactamase inhibitors potentially useful for the treatment of bacterial infections.

Impact Therapeutics Inc. has divulged heteroaryl compounds acting as ATP-dependent RNA helicase A (DHX9) inhibitors intended for use in the treatment of cancer.

Indiana Biosciences Research Institute Inc. and Indiana University have jointly identified tyrosine-protein kinase Lyn inhibitors described as potentially useful for the treatment of Alzheimer’s disease.